MaxCyte MXCT Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $33.03M-14.5% | $38.63M-6.4% | $41.29M-6.7% | $44.26M+30.6% | ||
| $6.22M-12.4% | $7.1M+49.7% | $4.74M-7.0% | $5.1M+39.8% | ||
| $26.8M-15.0% | $31.53M-13.7% | $36.55M-6.7% | $39.16M+29.5% | ||
| 81.2%-0.5pp | 81.6%-6.9pp | 88.5%0.0pp | 88.5%-0.8pp | ||
| $20.82M-6.3% | $22.23M-6.7% | $23.82M+22.1% | $19.51M+26.7% | ||
| $18.92M-29.0% | $26.66M-1.2% | $26.98M+44.6% | $18.65M+43.5% | ||
| $28.12M-5.3% | $29.69M-1.2% | $30.07M+16.4% | $25.83M+38.3% | ||
| $4.23M+2.0% | $4.14M+4.0% | $3.99M+57.6% | $2.53M+87.4% | ||
| $3.55M— | —— | —— | —— | ||
| $78.7M-4.9% | $82.73M-2.5% | $84.85M+27.5% | $66.52M+37.3% | ||
| $78.7M-4.9% | $82.73M-2.5% | $84.85M+27.5% | $66.52M+37.3% | ||
| -$51.9M-1.4% | -$51.2M-6.0% | -$48.3M-76.5% | -$27.36M-50.4% | ||
| -157.1%-24.6pp | -132.5%-15.6pp | -117%-55.2pp | -61.8%-8.2pp | ||
| $7.27M-28.3% | $10.14M-2.3% | $10.38M+165% | $3.92M+2,499% | ||
| $7.27M-28.3% | $10.14M-2.3% | $10.38M+174% | $3.79M+489% | ||
| -$44.63M-8.7% | -$41.06M-8.3% | -$37.92M— | —— | ||
| —— | —— | —— | —— | ||
| -$44.63M-8.7% | -$41.06M-8.3% | -$37.92M-60.9% | -$23.57M-23.5% | ||
| -135.1%-28.9pp | -106.3%-14.4pp | -91.8%-38.6pp | -53.3%+3.0pp | ||
| -$0.43-10.3% | -$0.39-5.4% | -$0.37-60.9% | -$0.23-4.5% | ||
| -$0.43-10.3% | -$0.39-5.4% | -$0.37-60.9% | -$0.23-4.5% | ||
| 425.4M+1.6% | 418.7M+1.5% | 412.6M+1.6% | 406.2M+19.1% | ||
| 425.4M+1.6% | 418.7M+1.5% | 412.6M+1.6% | 406.2M+15.4% | ||
| $3.55M— | —— | —— | —— | ||
| $7.27M-28.3% | $10.14M-2.3% | $10.38M+174% | $3.79M+489% | ||
| -$51.9M-1.4% | -$51.2M-6.0% | -$48.3M-76.5% | -$27.36M-50.4% | ||
| -$47.56M-1.4% | -$46.88M-6.2% | -$44.13M-78.9% | -$24.66M-47.1% | ||
| -$47.56M-1.4% | -$46.88M-6.2% | -$44.13M-78.9% | -$24.66M-47.1% | ||
| -144%-22.6pp | -121.4%-14.5pp | -106.9%-51.2pp | -55.7%-6.3pp | ||
| -$51.9M-1.4% | -$51.2M-6.0% | -$48.3M-76.5% | -$27.36M-50.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is MaxCyte's revenue?
- MaxCyte (MXCT) generated $32.3M in revenue over the trailing twelve months, down 14.3% year over year.
- Is MaxCyte profitable?
- MaxCyte is not currently profitable: it reported a net loss of $39.1M over the trailing twelve months, a -121.2% net margin.
- What are MaxCyte's profit margins?
- Gross margin is 80.5% and operating margin is -141.8%, with a -121.2% net margin.
- What is MaxCyte's earnings per share?
- MaxCyte's diluted EPS over the trailing twelve months is $-0.37.
- Where does MaxCyte's income statement data come from?
- Every line is extracted from MaxCyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
